VolitionRx (VNRX) Q2 2026 Earnings Call: Costs Fall as Nu.Q Pipeline Advances
Source Tradingkey
Key Takeaways
- VolitionRx Limited (NYSE American: VNRX) reported Q2 2026 revenue of approximately $0.4 million, broadly unchanged from Q2 2025. First-half revenue rose 112% year over year to $1.4 million.
- Q2 operating expenses fell 32% to $4.6 million from $6.7 million, reflecting the company’s cost-reduction program and a 27% year-over-year reduction in headcount.
- Net loss increased to $7.3 million from $6.3 million, primarily due to approximately $3 million of noncash accounting charges related to the Lind convertible notes.
- The Nu.Q NETs finger-prick lateral flow prototype showed approximately 90% correlation with the CE Mark automated assay in samples from critically ill patients with confirmed sepsis.
- Management is targeting a Nu.Q Lung Cancer reimbursement submission in France during Q3 2026, while emphasizing that reimbursement approval remains uncertain.
- Publication of the Nu.Q Vet feline cancer study is expected to trigger a $5 million contractual milestone payment. The prototype detected 86% of feline lymphomas at 97% specificity.
Key Financial Data
| Metric | Q2 2026 | Q2 2025 | Change / Commentary |
|---|---|---|---|
| Revenue | Approx. $0.4 million | Approx. $0.4 million | Broadly flat; higher Nu.Q Vet revenue was offset by lower Nu.Q Discover services revenue |
| First-half revenue | $1.4 million | — | Up 112% year over year |
| Operating expenses | $4.6 million | $6.7 million | Down 32% year over year |
| Operating loss | — | — | Down 34% year over year |
| Net loss | $7.3 million | $6.3 million | Increase mainly reflected approximately $3 million of noncash Lind note charges |
| Operating cash used | $5.2 million | $6.3 million | Lower year over year as cost savings began to take effect |
| Cash and cash equivalents | $2.8 million | $1.1 million at Dec. 31, 2025 | Q2 financing included $1.2 million from the ATM facility and $4.1 million from a public offering |
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
As of the European session on August 14, international spot copper prices (COPPER) continued to fluctuate near historical highs, trading around $14,070, down slightly by 0.3% intraday. De
WTI remains below $80.50 as traders monitor diplomatic efforts to reopen HormuzWest Texas Intermediate (WTI) oil price remains subdued for the third successive day, trading around $80.30 per barrel during the Asian hours on Friday. Crude oil prices edge lower as investors adopt a wait-and-see approach, closely monitoring diplomatic attempts to reopen the Strait of Hormuz.
West Texas Intermediate (WTI) oil price remains subdued for the third successive day, trading around $80.30 per barrel during the Asian hours on Friday. Crude oil prices edge lower as investors adopt a wait-and-see approach, closely monitoring diplomatic attempts to reopen the Strait of Hormuz.
Here is what you need to know on Thursday, August 13:
WTI declines below $82.50 as oil inventories rise far more than expectedWest Texas Intermediate (WTI), the US crude oil benchmark, is trading around $82.45 during the early Asian trading hours on Thursday. WTI declines on a larger-than-expected build in US crude oil inventories. Traders will closely monitor the developments surrounding US-Iran talks for fresh impetus.
West Texas Intermediate (WTI), the US crude oil benchmark, is trading around $82.45 during the early Asian trading hours on Thursday. WTI declines on a larger-than-expected build in US crude oil inventories. Traders will closely monitor the developments surrounding US-Iran talks for fresh impetus.
During Wednesday's Asian trading session, spot gold (XAUUSD) extended its rebound, reclaiming $4,400/oz. As of 11:08 Beijing time on August 12, spot gold was trading at $4,414.705/oz, up
